Dilaforette Ab

Karolinska Innovations Ab

Modus Therapeutics Ab

Mats Wahlgren

Hans-Peter Ekre

Anna Leitgeb

Ulf Lindahl

Erik Yngve Holmer

Per-Olov Eriksson

Stefania Tiddia

Lino Liverani

Dagmar Pikas

Antonio Barragan

Johan Carlson

Chen Qijun

Victor Fernandez

Stefania Tidia

The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria. 

Low anticoagulant heparins

The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.

Use of chemically modified heparin derivates in sickle cell disease

The present invention relates to carbohydrates capable of acting as receptors for malaria antigens present on the surfaces of malaria infected erythrocytes. The receptors according to the invention comprises negatively charged glycosaminoglycan-like moities, preferably sulphated. The invention also relates to novel malaria polypeptides capable of acting as ligands in relation to the receptors according to the invention. The invention also encompasses the use thereof as medicaments, pharmaceutical compositions containing the same as well as antibodies directed against said new ligands.

Malaria polypeptides

Growing community of inventors

Stocksund, Sweden

Mats Wahlgren